Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D 
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes (T2D). Integrated data from 9 phase II and III trials in people with T2D (N = 6005) were used to evaluate the effects of dulaglutide on estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR) and kidney adverse events (AEs). No significant differences in eGFR were observed during treatment for dulaglutide vs placebo, active comparators or insulin glargine the kidney (e.g. biguanides and some sulphonylureas) often require dosage adjustments, and many are contraindicated. [1] [2] [3] In addition, patients with T2D and CKD are at a higher risk of hypoglycaemia compared with patients with T2D because of decreased gluconeogenesis by the kidney as well as decreased clearance of insulin and of some other diabetes medications. 4 Diabetes medications not cleared by the kidney and associated with a low risk of hypoglycaemia would represent a clinically significant advance for patients with T2D
and CKD.
Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA). In phase II and phase III registration studies, dulaglutide was found to have superior glycaemic efficacy compared with placebo, exenatide, insulin glargine, metformin and sitagliptin. 5 Because of its large molecular size, dulaglutide is not cleared by the kidney, 5 but is presumably catabolized by proteolytic degradation. In a phase I study, no clinically relevant change in the pharmacokinetics of dulaglutide was observed in participants with low kidney function. 5 The primary objective of the present study was to evaluate the effects of dulaglutide on kidney function and safety in patients with T2D.
This study presents integrated data from 9 clinical trials (ClinicalTrials.gov): NCT00630825; NCT00791479; NCT01001104; NCT01149421; NCT01064687; NCT00734474; NCT01075282; NCT01191268; and NCT01126580.
| RESEARCH DESIGN AND METHODS
Integrated individual-level data from 6 completed phase II and III registration studies which evaluated dulaglutide doses of 0.75 and 1.5 mg, with treatment duration of at least 26 weeks, were used to evaluate the effect of dulaglutide on kidney function (Table S1 , Appendix S1). 5 In 2 studies, AWARD-1 and AWARD-5, after 26 weeks, participants receiving placebo were switched to dulaglutide or sitagliptin, respectively. 5 Data collected after the switch from placebo to active treatment were not included in the analyses of serum creatinine (sCr), estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). UACR was based on spot urine samples and was calculated as the ratio of urinary albumin (mg) to urinary creatinine (g).
Three additional placebo-controlled phase II studies, 5 which did not evaluate both 0.75 and 1.5 mg dulaglutide doses (and were of short treatment durations), were only included for the purpose of identifying potential acute renal failure adverse events (AEs) throughout the dulaglutide clinical development programme. These studies were not included in the evaluation of kidney function because of the short treatment period and the lack of both dulaglutide doses.
Details of the statistical analyses are presented in Appendix S1.
| RESULTS

| Demographics and baseline characteristics
A total of 6005 study participants received the study drug in the 9 completed phase II and III registration studies. At baseline, across the 9 studies, 4.4% (n = 265) of participants had persistent eGFR <60 mL/min/1.73 m 2 , 3% (n = 181) had persistent macroalbuminuria (defined as UACR >300 mg/g), and 7.1% (n = 425) had eGFR <60 mL/min/1.73 m 2 and/or macroalbuminuria. The 6 studies used to evaluate the effects of dulaglutide on kidney function included a broad range of patients with T2D whose diabetes duration ranged from 2.6 to 12.7 years (Table 1 ).
In the 3 placebo studies, proportions of participants who used antihypertensive medications, angiotensin-converting enzyme (ACE) inhibitors and angiotension receptor blockers (ARBs) were similar in the placebo arm and the dulaglutide arm (placebo 69.9%, 43.5% and 20.6%; dulaglutide 67.5%, 41.8% and 19.5%, respectively; P = .299).
Across all 6 studies, 67.6% of participants receiving dulaglutide used antihypertensive medications with 39.4% using ACE inhibitors and 20.5% using ARBs.
| Effects of dulaglutide on sCr, eGFR and UACR
In the 3 placebo-controlled studies, baseline sCr, eGFR and UACR values for placebo and the all-dulaglutide (0.75 mg dose and 1.5 mg dose groups combined) group were similar (Table S2 , Appendix S1).
No significant difference was observed in sCr or eGFR between placebo and the all-dulaglutide group over 26 weeks of treatment ( Figure 1A ,D). In response to treatment with dulaglutide or placebo up to 26 weeks, UACR decreased slightly in both groups ( Figure 1G ).
The decrease in UACR was slightly greater in the dulaglutide group compared with placebo (median percent change −16.7% vs −10.0%; Table S2 , Appendix S1]).
In the 5 phase III studies that evaluated dulaglutide vs active comparator, baseline sCr and eGFR levels were comparable between the all-dulaglutide and active comparator groups (Table S2 , Appendix S1). No significant difference was observed in sCr or eGFR between the 2 groups with treatment up to 104 weeks ( Figure 1B ,E). Baseline UACR was slightly higher in the active comparator group (Table S2, Appendix S1 and Figure 1H ). In response to treatment with dulaglutide or active comparator up to 104 weeks, UACR tended to decrease in both groups ( Figure 1H ). UACR levels were slightly lower in the dulaglutide group compared with the active comparator group ( Figure 1H ). At 26 weeks, median percent changes were −20.0% vs −12.5%, respectively (Table S2 , Appendix S1).
In the 2 phase III studies that evaluated dulaglutide vs insulin glargine, baseline sCr and eGFR levels were similar in the all-dulaglutide and insulin glargine groups (Table S2 , Appendix S1). No significant difference was observed in sCr or eGFR between the 2 groups with treatment up to 52 weeks ( Figure 1C,F) . Baseline UACR was slightly higher in the insulin glargine group (Table S2 , Appendix S1 and Figure 1I ). UACR levels tended to be lower in the dulaglutide group compared with the insulin glargine group ( Figure 1I and Table S2 , Appendix S1). At 26 weeks, median percent changes in UACR from baseline were −20.0% for dulaglutide vs −9.4% for insulin glargine. At 52 weeks, the median percent decrease in UACR was −16.7% for dulaglutide and −3.7% for insulin glargine (Table S2 , Appendix S1).
| Proportions of participants with 30% or 40% decline in eGFR
The number of participants who experienced a 30% or 40% decline in eGFR over time was not significantly different for dulaglutidetreated participants compared with placebo and all active comparators combined (Table S3 , Appendix S1); however, in comparison with insulin glargine, there were significantly fewer dulaglutide-treated participants who experienced a 40% decline in eGFR at any point during a 1-year treatment period (0.26% vs 1.25%; P = .012 [Table S3 ,
Appendix S1]).
| AEs reflecting potential acute renal failure
In the 9 completed phase II and III studies, 4006 received dulaglutide (3531 patient-years), 703 received placebo (284 patient-years) and 1541 received active comparator (1722 patient-years). Some study participants received placebo followed by dulaglutide (n = 121) or sitagliptin (n = 124) and are included in the totals for each drug. 5 AEs reflecting potential acute renal failure (Table S4 , Appendix S1) were reported at rates of 3.4 (n = 12), 1.7 (n = 3) and 7.0 (n = 2) events per 1000 patient-years of exposure for dulaglutide, active comparators and placebo, respectively. Details regarding the 12 dulaglutide participants who reported an AE reflecting potential acute renal failure are included in Appendix S1. 2 eGFR was calculated based on the CKD-EPI equation 6 and serum creatinine value, using the highest measured value of eGFR (CKD-EPI).
| DISCUSSION
3 Patients were included if they met criteria for either the UACR > 300 mg/g or eGFR (CKD-EPI) <60 mL/min/1.73 m 2 group as shown in Footnotes 4 and 5 below. 4 Patients were included if UACR >300 mg/g at all measured timepoints during baseline. renoprotective effects by decreasing albuminuria through GLP-1-mediated anti-inflammatory effects, amelioration of oxidative stress and vascular endothelium protection in the kidney. [27] [28] [29] [30] In addition, GLP-1 is also involved in sodium and water homeostasis via stimulation of natriuresis and diuresis, [31] [32] [33] [34] [35] 38, 39 To determine the clinical significance of this albuminuria-lowering signal, the effects of dulaglutide should be further evaluated in patients with elevated UACR at baseline.
Limitations of the present study include the inclusion of a small number of participants with low eGFR or high levels of albuminuria.
In addition, the studies included in the present analyses were not prospectively designed to evaluate the effects of dulaglutide on kidney function. The study's strengths include the availability of individuallevel data at common timepoints from a large number of participants with T2D, relatively long treatment periods, and the availability of both placebo and active comparator data.
In 
